Nurix Therapeutics (NRIX) vs uniQure N.V. (QURE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Nurix Therapeutics (NRIX) has outperformed uniQure N.V. (QURE) over the past year, losing 23.3% versus a loss of 30.4%. Over five years, QURE leads with a -32.9% price change compared with -57.3% for NRIX. Nurix Therapeutics is the larger company by market cap ($1.40 billion vs $1.36 billion), about 1.0 times the size.
Nurix Therapeutics converts more of its revenue into profit, with a net margin of -314.9% versus -1236.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRIX | QURE |
|---|---|---|
| Share price | $12.85 | $19.35 |
| Market cap | $1.40B | $1.36B |
| 1-day change | -5.55% | -4.35% |
| YTD return | -32.26% | -19.14% |
| 1-year return | -23.33% | -30.42% |
| 5-year return | -57.25% | -32.86% |
| P/E ratio (TTM) | 5.29 | — |
| EPS (TTM) | $2.43 | $-3.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $83.98M | $16.10M |
| Revenue growth (YoY) | +53.95% | -40.64% |
| Net income (latest FY) | $-264.46M | $-198.97M |
| Gross margin | — | 89.53% |
| Operating margin | -340.16% | -1151.38% |
| Net margin | -314.90% | -1236.00% |
| 52-week high | $28.23 | $51.72 |
| 52-week low | $12.83 | $8.73 |
| Distance from 52-week high | -54.50% | -62.59% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +160.80% | +207.03% |
| Average volume | 2.47M | 2.26M |
| Shares outstanding | 109.25M | 70.14M |
| Employees | 317 | 221 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Nurix Therapeutics is more profitable, keeping -314.9 cents of every revenue dollar as net income versus -1236.0 cents for uniQure N.V..
- Nurix Therapeutics grew revenue faster in its latest fiscal year (+53.95% vs -40.64%).
About Nurix Therapeutics
NRIX stock →Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
About uniQure N.V.
QURE stock →uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 221 employees
NRIX vs QURE FAQ
Which is bigger, Nurix Therapeutics or uniQure N.V.?
Nurix Therapeutics (NRIX) is larger, with a market capitalization of $1.40B compared with $1.36B for uniQure N.V. (QURE).
Which stock has performed better over the past year, NRIX or QURE?
NRIX returned -23.33% over the past 12 months, compared with -30.42% for QURE (price return, excluding dividends). Past performance does not predict future results.
Are Nurix Therapeutics and uniQure N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.